In this interview from the 2026 AACR Annual Meeting, Dr Roberto Borea of The Ohio State University details an investigation into the "obesity paradox" within non–small cell lung cancer (NSCLC). While obesity is typically linked to poorer outcomes in various malignancies, patients with NSCLC with a higher body mass index (BMI) often exhibit improved survival rates. Dr Borea’s research seeks to move past this clinical observation to uncover the underlying molecular mechanisms driving this phenomenon.
Key Takeaways
- Molecular Drivers of the "Obesity Paradox": Unlike other cancers where obesity worsens outcomes, NSCLC patients with higher BMIs often show better survival. This research uses RNA sequencing to identify biological reasons for this, such as redox pathway enrichment in obese patients and T-cell activation in overweight patients.
- Treatment-Specific Survival Benefits: The survival advantage for higher-BMI patients is most pronounced in those receiving immunotherapy (IO) and tyrosine kinase inhibitors (TKIs).
Utilizing a consortium database—a collaborative effort between Ohio State and the Moffitt Cancer Center—the research team analyzed clinical data alongside RNA and whole-exome sequencing from a cohort of nearly 300 patients. The study categorized patients into four BMI groups: obese, overweight, normal weight, and underweight. By performing pathway enrichment analysis on the RNA sequencing data, the researchers identified distinct biological signatures across these groups. Notably, obese patients showed significant enrichment in redox pathways, while overweight patients exhibited T-cell activation that was not present in the normal-weight cohort.
Beyond general survival trends, the study’s most striking findings emerged when the data was sub-categorized by treatment type: chemotherapy, immunotherapy (IO), and tyrosine kinase inhibitors (TKIs). Dr Borea noted that the survival advantage associated with a higher BMI was particularly relevant in the immunotherapy and TKI groups. These results suggest that a patient's metabolic status may actively influence the efficacy of modern targeted and immune-based therapies.
Looking ahead, Dr Borea emphasizes that these results are preliminary and exploratory. The next phase of research involves deeper RNA sequencing within specific treatment categories to determine if the enriched pathways in high-BMI patients directly dictate treatment response. This work represents a critical step toward understanding how host factors like BMI can be used to better predict outcomes and personalize therapy in NSCLC.
